| Project/Area Number |
25460659
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Tokyo Women's Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
林 和彦 東京女子医科大学, 医学部, 教授 (10208613)
中島 豪 東京女子医科大学, 医学部, 助教 (80338996)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KANNO Hitoshi 東京女子医科大学, 医学部, 教授 (70221207)
|
|---|
| Project Period (FY) |
2013-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 遺伝子多型 / CPT-11 / バイオマーカー / DMET / UGT1A1 |
|---|
| Outline of Final Research Achievements |
Irinotecan (CPT-11) is one of the key drug in major solid tumors. We investigated the relationship between gene polymorphisms and adversed events (especially neutropenia and diarrhea) in patients who received CPT-11, using DMET microarray technique. No gene polymorphism was found which significantly related to Grade 4 neutropenia. However, there was one SNP which was significantly related to Grade 2 or more diarrhea. We confirmed this relationship among different cohort of 24 patients, and found similar relationship. We also verified the relationship between UGT1A1 *6 polymorphism, which was already known as a CPT-11 biomarker, and neutropenia.
|
